Based on 1 Customer Validation
Polyinosinic-polycytidylic acid (Poly(I:C)) (GMP Like) is the GMP Like class Polyinosinic-polycytidylic acid (HY-107202), and can be used as pharmaceutical excipients. Polyinosinic-polycytidylic acid (Poly(I:C)) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid can directly trigger cancer cells to undergo apoptosis.
For research use only. We do not sell to patients.
- Purity: 90.5%
- CAS No.: 24939-03-5
- Formula: (C10H13N4O8P)x.(C9H14N3O8P)x
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Polyinosinic-polycytidylic acid (0.5-5 μg/mL, 3-24 h) (GMP Like) induces a dose- and time-dependent increase in paracellular permeability of immortalized airway epithelial cells[4].
Polyinosinic-polycytidylic acid (5 μg/mL, 24 h) (GMP Like) does not have cytotoxicity to 16HBE14o- cells[4].
Polyinosinic-polycytidylic acid (5 μg/mL, 6 h) (GMP Like) induces disruption of epithelial apical junctional complexes
(AJCs) and tight junctions (TJs) in 16HBE14o- cells[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:16HBE14o- cells
-
Concentration:5 μg/mL
-
Incubation Time:24 h
-
Result:Did not lead to significant accumulation of LDH in cell-culture medium.
Polyinosinic-polycytidylic acid (10 μg/mouse, Intraperitoneal injection, single dose) (GMP Like) decreases lung tumor growth in mice[3].
Polyinosinic-polycytidylic acid (1.25 mg/kg, Intraperitoneal injection, single dose) (GMP Like) exerts therapeutic effects against cerebral I/R injury through the downregulation of TLR4/MyD88 signaling via TLR3 in MCAO model mice[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Middle cerebral artery occlusion (MCAO) model mice[5]
-
Dosage:1.25 mg/kg
-
Administration:Intraperitoneal injection (i.p.)
-
Result:Reduced focal cerebral I/R injury. Increased the expression of Bcl2, Hsp27, and Hsp70, decreased Bax expression, and reduced cellular degeneration and apoptosis. Protected against cerebral ischemia and conferred protection against cerebral I/R injury through the downregulation of TLR4 signaling via TLR3.
-
Animal Model:Lung tumor-bearing mice[3]
-
Dosage:10 μg/mouse
-
Administration:Intraperitoneal injection (i.p.)
-
Result:Induced a significant decrease in the growth of pulmonary metastases in tumor-bearing mice. Reduced the amount of lung foci to ≈ 40%. Significantly increased BAL fluid cell numbers. Increased the level of INF-γ and IL-17A, decreased the levels of IL-13. Increased TLR3 expression.
Chemical Information
-
CAS No. 24939-03-5
-
Appearance Solid
-
Formula (C10H13N4O8P)x.(C9H14N3O8P)x
-
Color White to off-white
-
SMILES
O[C@H]1[C@@H](O[C@H](COP(O)(O)=O)[C@H]1O)N2C3=C(C(NC=N3)=O)N=C2.O[C@H]4[C@H](N5C(N=C(N)C=C5)=O)O[C@H](COP(O)(O)=O)[C@H]4O.[x].[x]
-
Synonyms
Poly(I:C) (GMP Like)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Cheng Y, Xu F. Anticancer function of polyinosinic-polycytidylic acid [J]. Cancer biology & therapy, 2010, 10(12): 1219-1223. [Content Brief]
[2]. Deleidi M, Hallett P J, Koprich J B, et al. The Toll-like receptor-3 agonist polyinosinic: polycytidylic acid triggers nigrostriatal dopaminergic degeneration [J]. Journal of Neuroscience, 2010, 30(48): 16091-16101. [Content Brief]
[3]. Forte G, Rega A, Morello S, et al. Polyinosinic-polycytidylic acid limits tumor outgrowth in a mouse model of metastatic lung cancer [J]. The Journal of Immunology, 2012, 188(11): 5357-5364. [Content Brief]
[4]. Rezaee F, Meednu N, Emo J A, et al. Polyinosinic: polycytidylic acid induces protein kinase D–dependent disassembly of apical junctions and barrier dysfunction in airway epithelial cells [J]. Journal of Allergy and Clinical Immunology, 2011, 128(6): 1216-1224. e11. [Content Brief]
[5]. Wang P F, Fang H, Chen J, et al. Polyinosinic-polycytidylic acid has therapeutic effects against cerebral ischemia/reperfusion injury through the downregulation of TLR4 signaling via TLR3 [J]. The Journal of Immunology, 2014, 192(10): 4783-4794. [Content Brief]
[6]. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001;413(6857):732-738. [Content Brief]
[7]. Matsumoto M, Kikkawa S, Kohase M, Miyake K, Seya T. Establishment of a monoclonal antibody against human Toll-like receptor 3 that blocks double-stranded RNA-mediated signaling. Biochem Biophys Res Commun. 2002;293(5):1364-1369. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Polyinosinic-polycytidylic acid (GMP Like) Related Classifications
HY-107202GL Related Classifications
Powered by Bioz